Linked Life Data

11711196

Source:http://linkedlifedata.com/resource/pubmed/id/11711196

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2001-11-16
pubmed:abstractText
Pharmacogenomics is the study of the inherited basis of differences in response to drugs. These interindividual differences are often more than tenfold; a 'slow metabolizer' or 'low-responsive' individual might therefore require ten times less than the recommended dose of a drug than a 'rapid metabolizer' or 'high-responsive' person, and the slow metabolizer is often more likely to experience drug toxicity than a rapid metabolizer. Our knowledge is developing rapidly to the point that the physician will soon use DNA-based tests to aid in decision-making with respect to the most appropriate drug and dosage given to each patient. If the patient's DNA is available, however, what boundaries should be placed on that DNA? If the patient's genotype becomes known to the physician (and presumably to the patient him- or herself), what ethical questions might arise and how will they be resolved? This article discusses these issues and outlines some of the possible solutions.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0167-7799
pubmed:author
pubmed:issnType
Print
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
519-23
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed:year
2001
pubmed:articleTitle
Pharmacogenomics: out of the lab and into the community.
pubmed:affiliation
Center for Environmental Genetics, Dept of Environmental Health, and Dept of Pediatrics/Division of Human Genetics, University of Cincinnati Medical Center, PO Box 670056, Cincinnati, OH 45267-0056, USA. dan.neubert@uc.edu
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.